» Articles » PMID: 18723672

Dysregulation of MicroRNAs After Myocardial Infarction Reveals a Role of MiR-29 in Cardiac Fibrosis

Overview
Specialty Science
Date 2008 Aug 30
PMID 18723672
Citations 921
Authors
Affiliations
Soon will be listed here.
Abstract

Acute myocardial infarction (MI) due to coronary artery occlusion is accompanied by a pathological remodeling response that includes hypertrophic cardiac growth and fibrosis, which impair cardiac contractility. Previously, we showed that cardiac hypertrophy and heart failure are accompanied by characteristic changes in the expression of a collection of specific microRNAs (miRNAs), which act as negative regulators of gene expression. Here, we show that MI in mice and humans also results in the dysregulation of specific miRNAs, which are similar to but distinct from those involved in hypertrophy and heart failure. Among the MI-regulated miRNAs are members of the miR-29 family, which are down-regulated in the region of the heart adjacent to the infarct. The miR-29 family targets a cadre of mRNAs that encode proteins involved in fibrosis, including multiple collagens, fibrillins, and elastin. Thus, down-regulation of miR-29 would be predicted to derepress the expression of these mRNAs and enhance the fibrotic response. Indeed, down-regulation of miR-29 with anti-miRs in vitro and in vivo induces the expression of collagens, whereas over-expression of miR-29 in fibroblasts reduces collagen expression. We conclude that miR-29 acts as a regulator of cardiac fibrosis and represents a potential therapeutic target for tissue fibrosis in general.

Citing Articles

MicroRNAs in atrial fibrillation - have we discovered the Holy Grail or opened a Pandora's box?.

Balan A, Scridon A Front Pharmacol. 2025; 16:1535621.

PMID: 40012622 PMC: 11861496. DOI: 10.3389/fphar.2025.1535621.


Bioactive Hydrogel Supplemented with Stromal Cell-Derived Extracellular Vesicles Enhance Wound Healing.

Galbiati M, Maiullari F, Ceraolo M, Bousselmi S, Fratini N, Gega K Pharmaceutics. 2025; 17(2).

PMID: 40006529 PMC: 11859224. DOI: 10.3390/pharmaceutics17020162.


Engineering Lipid Nanoparticles to Enhance Intracellular Delivery of Transforming Growth Factor-Beta siRNA (siTGF-β1) via Inhalation for Improving Pulmonary Fibrosis Post-Bleomycin Challenge.

Deng X, Yang Y, Gan L, Duan X, Wang X, Zhang J Pharmaceutics. 2025; 17(2).

PMID: 40006524 PMC: 11859093. DOI: 10.3390/pharmaceutics17020157.


MicroRNA-26b inhibits cardiac remodeling after myocardial infarction by targeting ring finger protein 6 expression.

Tang C, Su Q, Zhao H, Sui H, Liang J, Zhu L Arch Med Sci. 2025; 20(6):2009-2021.

PMID: 39967940 PMC: 11831335. DOI: 10.5114/aoms/130649.


miR-1233-3p Inhibits Angiopoietin-1-Induced Endothelial Cell Survival, Migration, and Differentiation.

Sanchez V, Harel S, Saub A, Mayaki D, Hussain S Cells. 2025; 14(2).

PMID: 39851503 PMC: 11763389. DOI: 10.3390/cells14020075.


References
1.
Van Rooij E, Olson E . MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest. 2007; 117(9):2369-76. PMC: 1952642. DOI: 10.1172/JCI33099. View

2.
Kapoun A, Liang F, OYoung G, Damm D, Quon D, White R . B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res. 2004; 94(4):453-61. DOI: 10.1161/01.RES.0000117070.86556.9F. View

3.
Krutzfeldt J, Rajewsky N, Braich R, Rajeev K, Tuschl T, Manoharan M . Silencing of microRNAs in vivo with 'antagomirs'. Nature. 2005; 438(7068):685-9. DOI: 10.1038/nature04303. View

4.
Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E . MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A. 2007; 104(40):15805-10. PMC: 2000384. DOI: 10.1073/pnas.0707628104. View

5.
Hammond S . MicroRNAs as oncogenes. Curr Opin Genet Dev. 2005; 16(1):4-9. DOI: 10.1016/j.gde.2005.12.005. View